Paper Title
A STUDY ON EFFICACY OF PRE-MEDICATIONS IN THE MANAGEMENT OF HYPERSENSITIVITY REACTIONS ASSOCIATED WITH CHEMOTHERAPY AMONG BREAST CANCER PATIENTS
Article Identifiers
Authors
Dr. MUCHUKOTA SUSHMA , PRIYANKA C , SWATHI , ALKAYUM AHMAD , IFTHIKAR, Dr. C D SARASWATHI, SABITHA SUJEETH
Keywords
Breast cancer, Hypersensitivity reactions, Premedication, Desensitization
Abstract
ABSTRACT: - Background: The estimation of 2.3 million (11.7% of all cancer cases) new cases of breast cancer diagnosed every year globally, the death rate increased over the last 3 decades, it is the 5th leading cause of mortality worldwide with 685000 deaths. Chemotherapy is a crucial component of breast cancer treatment, yet it is often accompanied by the risk of hypersensitivity reactions (HSRs). Objective: Evaluating hypersensitivity reactions in breast cancer patients involves assessing the effectiveness of premedication, treatment methods, and standardized desensitization protocols to manage reactions and implementing risk management measures. Methodology: This is Hospital based prospective observational study was conducted in ESI hospital Indira nagar Bangalore, the present study was conducted among 85 patients for a period of six months from April 2023 – September 2023, involves breast cancer patients receiving chemotherapy. Results: Among the 85 breast cancer patients in our study, 40% were in stage 2 were classified as having a major disease severity, while only 5.88% of those in stage 4 had the lowest severity. Hypersensitivity reactions were prevalent, with 64.7% experiencing grade Ⅰ and Ⅱ reactions, and 35.29% having grade Ⅲ and Ⅳ reactions. Notably, platinum agents, specifically carboplatin and oxaliplatin, were responsible for hypersensitivity reactions in 54.11% of cases, while taxanes (paclitaxel and docetaxel) were associated with reactions in 32.9% of cases. Additionally, 38% of the participants received monoclonal antibodies as part of their treatment. Conclusion: Breast cancer patients receiving chemotherapy, the present study found significant presence of hypersensitivity reactions, with the majority falling into grade Ⅰ and Ⅱ categories. These reactions were most commonly associated with platinum agents and taxanes. A substantial portion of patients received monoclonal antibodies as part of their treatment. These findings underscore the need for tailored premedication protocols and risk management measures to improve the safety and efficacy of breast cancer therapy, particularly for those at risk of hypersensitivity reactions.
Downloads
How To Cite (APA)
Dr. MUCHUKOTA SUSHMA, PRIYANKA C, SWATHI, ALKAYUM AHMAD, & IFTHIKAR, Dr. C D SARASWATHI, SABITHA SUJEETH (December-2023). A STUDY ON EFFICACY OF PRE-MEDICATIONS IN THE MANAGEMENT OF HYPERSENSITIVITY REACTIONS ASSOCIATED WITH CHEMOTHERAPY AMONG BREAST CANCER PATIENTS. INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT, 8(12), b792-b800. https://ijnrd.org/papers/IJNRD2312199.pdf
Issue
Volume 8 Issue 12, December-2023
Pages : b792-b800
Other Publication Details
Paper Reg. ID: IJNRD_210856
Published Paper Id: IJNRD2312199
Downloads: 000121987
Research Area: Engineering
Country: -, -, India
Published Paper PDF: https://ijnrd.org/papers/IJNRD2312199.pdf
Published Paper URL: https://ijnrd.org/viewpaperforall?paper=IJNRD2312199
About Publisher
Journal Name: INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT(IJNRD)
ISSN: 2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar | ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Publisher: IJNRD (IJ Publication) Janvi Wave | IJNRD.ORG | IJNRD.COM | IJPUB.ORG
Licence
This work is licensed under a Creative Commons Attribution 4.0 International License and The Open Definition
Publication Timeline
Article Preview: View Full Paper
Call For Paper
IJNRD is a Scholarly Open Access, Peer-reviewed, and Refereed Journal with a High Impact Factor of 8.76 (calculated by Google Scholar & Semantic Scholar | AI-Powered Research Tool). It is a Multidisciplinary, Monthly, Low-Cost Journal that follows UGC CARE 2025 Peer-Reviewed Journal Policy norms, Scopus journal standards, and Transparent Peer Review practices to ensure quality and credibility. IJNRD provides indexing in all major databases & metadata repositories, a citation generator, and Digital Object Identifier (DOI) for every published article with full open-access visibility.
The INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) aims to advance applied, theoretical, and experimental research across diverse fields. Its goal is to promote global scientific information exchange among researchers, developers, engineers, academicians, and practitioners. IJNRD serves as a platform where educators and professionals can share research evidence, models of best practice, and innovative ideas, contributing to academic growth and industry relevance.
Indexing Coverage includes Google Scholar, SSRN, ResearcherID-Publons, Semantic Scholar (AI-Powered Research Tool), Microsoft Academic, Academia.edu, arXiv.org, ResearchGate, CiteSeerX, ResearcherID (Thomson Reuters), Mendeley, DocStoc, ISSUU, Scribd, and many more recognized academic repositories.
How to submit the paper?
By Our website
Click Here to Submit Paper Online
Important Dates for Current issue
Paper Submission Open For: October 2025
Current Issue: Volume 10 | Issue 10 | October 2025
Impact Factor: 8.76
Last Date for Paper Submission: Till 31-Oct-2025
Notification of Review Result: Within 1-2 Days after Submitting paper.
Publication of Paper: Within 01-02 Days after Submititng documents.
Frequency: Monthly (12 issue Annually).
Journal Type: IJNRD is an International Peer-reviewed, Refereed, and Open Access Journal with Transparent Peer Review as per the new UGC CARE 2025 guidelines, offering low-cost multidisciplinary publication with Crossref DOI and global indexing.
Subject Category: Research Area
Call for Paper: More Details
